19-33387892-C-T
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM2PP3_StrongPP5_Very_Strong
The NM_000285.4(PEPD):c.1342G>A(p.Gly448Arg) variant causes a missense, splice region change. The variant allele was found at a frequency of 0.0000364 in 1,564,210 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 2/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_000285.4 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
PEPD | NM_000285.4 | c.1342G>A | p.Gly448Arg | missense_variant, splice_region_variant | 14/15 | ENST00000244137.12 | |
PEPD | NM_001166056.2 | c.1219G>A | p.Gly407Arg | missense_variant, splice_region_variant | 12/13 | ||
PEPD | NM_001166057.2 | c.1150G>A | p.Gly384Arg | missense_variant, splice_region_variant | 12/13 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
PEPD | ENST00000244137.12 | c.1342G>A | p.Gly448Arg | missense_variant, splice_region_variant | 14/15 | 1 | NM_000285.4 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000394 AC: 6AN: 152232Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000179 AC: 3AN: 167316Hom.: 0 AF XY: 0.0000221 AC XY: 2AN XY: 90520
GnomAD4 exome AF: 0.0000361 AC: 51AN: 1411860Hom.: 0 Cov.: 31 AF XY: 0.0000444 AC XY: 31AN XY: 697646
GnomAD4 genome AF: 0.0000394 AC: 6AN: 152350Hom.: 0 Cov.: 33 AF XY: 0.0000537 AC XY: 4AN XY: 74502
ClinVar
Submissions by phenotype
Prolidase deficiency Pathogenic:6
Pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Feb 25, 2016 | The p.Gly448Arg variant in PEPD has been reported in 6 individuals with prolidas e deficiency. Three of these individuals were homozygous and three compound hete rozygous with another pathogenic variant in PEPD (Ledoux 1994, Lupi 2006, Forlin o 2002). This variant has also been identified in 0.027% (2/7412) of European ch romosomes by the Exome Aggregation Consortium (ExAC, http://exac.broadinstitute. org; dbSNP rs121917724). Although this variant is seen in the general population , its frequency is consistent with a recessive carrier frequency. In addition, i n vitro functional studies provide some evidence that the p.Gly448Arg variant ma y impact protein function (Ledoux 1996, Besio 2013). In summary, this variant me ets our criteria to be classified as pathogenic for prolidase deficiency in an a utosomal recessive manner based upon its co-occurrence in trans with other patho genic variants in patients, low frequency in controls and functional evidence. - |
Pathogenic, criteria provided, single submitter | clinical testing | Rady Children's Institute for Genomic Medicine, Rady Children's Hospital San Diego | May 14, 2019 | This variant has been previously reported as a homozygous or compound heterozygous change in multiple patients with prolidase deficiency (PMID: 8198124, 17142620). Studies using patient fibroblast lines and recombinant prolidase demonstrated that this variant leads to decreased catalytic efficiency, thermal stability and cofactor binding (PMID: 23516557). Additionally, an in vitro experiment in COS-1 cells demonstrated that this variant reduces prolidase activity to undetectable levels (PMID: 8900231). This variant has been classified as Pathogenic by a clinical diagnostic laboratory in the ClinVar database (Variation ID: 213). It is present in the heterozygous state in the gnomAD population database at a frequency of .003% (5/193670) and thus is presumed to be rare. The c.1342G>A (p.Gly448Arg) variant is predicted by multiple in silico tools to have a deleterious effect on protein function. Based on the available evidence, the c.1342G>A (p.Gly448Arg) variant is classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Dec 11, 2018 | The PEPD c.1342G>A (p.Gly448Arg) missense variant has been reported in four studies in which it is found in a total of eight individuals with prolidase deficiency (PD). The variant was found in five individuals in a homozygous state, including a sibling pair, and in three compound heterozygotes, two of whom were related (Ledoux et al. 1994; Forlino et al. 2002; Lupi et al. 2006; Vestita et al. 2017). Ledoux et al. (1994), Lupi et al. (2006) and Besio et al. (2013) demonstrated that prolidase activity in fibroblasts from patients with PD with the p.Gly448Arg variant was reduced to <2% to 13.1% when compared to controls. In addition, transient expression of the p.Gly448Arg variant in COS1 cells produced an inactive enzyme (Ledoux et al. 1996), and a recombinant PEPD enzyme containing the p.Gly448Arg variant showed very low catalytic efficiency, thermal instability, and changes in protein conformations (Besio et al. 2013). Forlino et al. (2002) also showed that cultured PD patient fibroblasts with the p.Gly448Arg variant exhibited multiple cell structure abnormalities. This variant was absent in 150 control chromosomes and is reported at a frequency of 0.000036 in the European (non-Finnish) population. Based on the collective evidence, the p.Gly448Arg variant is classified as pathogenic for prolidase deficiency. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Oct 01, 2002 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Knight Diagnostic Laboratories, Oregon Health and Sciences University | Aug 29, 2017 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Oct 27, 2021 | - - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 21, 2024 | This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 448 of the PEPD protein (p.Gly448Arg). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This missense change has been observed in individual(s) with prolidase deficiency (PMID: 8198124, 12384772, 17142620, 25460580). ClinVar contains an entry for this variant (Variation ID: 213). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Experimental studies have shown that this missense change affects PEPD function (PMID: 8900231, 23516557). For these reasons, this variant has been classified as Pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at